Architecting the Metabolic Future: Why Your Brand is Only as Strong as Your Telehealth Infrastructure
In this multi-part series, we will explore how to build scalable telehealth infrastructure for GLP-1 and weight loss programs within the weight management and obesity care vertical end market.
This will include a breakdown of how to bridge eCommerce and compliant telehealth delivery to meet the demands of users and patients seeking care and how to qualify patients for the right care delivery mechanisms. It will also explore bringing together scalable, trustworthy partners across the value chain (brands, doctors/clinicians, lab/diagnostic companies, and pharmacies) to create a sustainable business model for metabolic healthcare delivery.
The Rise of GLP-1 Telehealth and Direct-to-Consumer Weight Loss Platforms
GLP-1 treatments have transformed the obesity and weight management market and created a renewed interest and focus on metabolic health as a key subvertical.
As a result, entire industries and business models have emerged to help solve (and monetize) obesity care and weight management, including many telehealth brands and equivalent direct-to-patient channels from the large biotech and pharmaceutical companies.
Based on the two ‘gold standard’ institutions that provide market sizing of the United States GLP-1 market, Goldman Sachs and Morgan Stanley, it is estimated that as of April 2026, 19 million patients are forecasted to have taken or on a GLP-1 medication with a total addressable market size of over $100 billion.
In these same forecasted estimates, by 2035, it is projected that over 55 million of the United States population will be on “anti-obesity” treatments like GLP-1s, an absolute increase of 189% across the next decade.
This expansive market is headlined by the two leading pharmaceutical companies, Eli Lilly and Novo Nordisk, as well as others in early and late-stage pipelines for drug innovation and development, like Metsera (recently acquired by Pfizer) and Viking Therapeutics.
Beyond this, there has been a rise of interest in direct-to-patient and direct-to-consumer access to these treatments (via channels like LillyDirect and NovoCare), as well as subscription-based businesses (leaders in this type of business include Ro, Hims & Hers, Noom).
The latter category of businesses often bring together a holistic, integrated package offering that combines access to medications (branded and compounded), along with a patient experience that includes interventional lifestyle monitoring, embedded patient data tracking (such as how body-mass index or BMI ratios trend), and other non-prescription interventions to help provide better health outcomes to patients beyond just a GLP-1 medication.
Building for Success in 2026 and Beyond with Scalable Telehealth Infrastructure
Under all of these entity types that are involved across the GLP-1, weight loss, and metabolic health marketplace is a common thread - telehealth infrastructure.
Our team at MD Integrations is often asked about how to engineer and design a proper structure - and which components they need to buy, build, or partner with to be successful and sustainable.
There is no one “silver bullet” or answer that works for all entity types at different stages of funding, growth, scale, and sophistication, but there are common patterns and clues that show what “success” looks like, and how to build towards it when talking about telehealth infrastructure.
That telehealth infrastructure typically consists of elements that power the direct-to-patient access, initial care delivery, engagement, and longitudinal care access.
It also keeps patients adhering to the proper titration schedules of the GLP-1 medications, weave in lifestyle interventions such as diet and exercise, and provide education and access to physicians and clinicians for common workflows such as administering the subcutaneous injections, reporting side effects/adverse events, and providing the necessary data to show the trendline of the efficacy of these combined efforts to manage metabolic health.
In this four-part series, we will break down telehealth infrastructure into four core components and how each helps to deliver a specific value proposition to create a metabolic health ecosystem that is comprehensive, scalable, and compliant in the expansive weight management and obesity care market.
The four components are:
- The Medical Engine: 50-State Provider Networks and Protocols
- The Integrated Pharmacy and Supply Chain Hub
- The Digital and Patient Experience Companion: Monitoring and Management
- The Data and Efficacy Ledger: Longitudinal Outcome Management
Each of these coexist in unison to drive different outcomes for telehealth brands, patients, and other constituents like the physicians/clinicians and the pharmacies / lab and diagnostic companies.
And within each of these pillars, there are key technology tools, platforms, and opportunities to weave in compliant artificial intelligence and automation that add speed, personalization, and create a connected bridge between eCommerce and medical care delivery.
Follow along for Part Two of the series, where we will unpack the importance and critical component of The Medical Engine in telehealth infrastructure, and how it provides scalability, quality of care, and increases patient access to metabolic health solutions like GLP-1 medications and weight management/obesity care interventions.
Please reach out to our team at MD Integrations to learn how you can launch and scale your telehealth brand compliantly.